Suvretta Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Suvretta Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-99,999	Closed	-$990K	–	96
2022 Q2	$990K	Hold	99,999	–	–	0.04%	84
2022 Q1	$984K	Hold	99,999	–	–	0.03%	80
2021 Q4	$976K	Hold	99,999	–	–	0.02%	87
2021 Q3	$978K	Hold	99,999	–	–	0.02%	98
2021 Q2	$984K	Hold	99,999	–	–	0.01%	115
2021 Q1	$998K	Hold	99,999	–	–	0.01%	99
2020 Q4	$1M	Buy	+99,999	New	+$1.01M	0.01%	97

Other funds holding EUCR

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Suvretta Capital Management's EUCR Position: Q3 2022 in Review

Suvretta Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2022, closing a stake of 99,999 shares — an estimated $990K sold.

Suvretta Capital Management first reported a position in EUCR in Q4 2020 and held it in 7 quarters. The position peaked at $1M in Q4 2020. 38 funds tracked by Wall St. Rank hold EUCR as of Q3 2022.

Suvretta Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Suvretta Capital Management sold 99,999 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2022, an estimated $990K.
Suvretta Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2020 and held it in 7 quarters.
Suvretta Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1M in Q4 2020.
38 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2022.

Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.